Literature DB >> 20457673

A multilevel analysis of trimethoprim and ciprofloxacin prescribing and resistance of uropathogenic Escherichia coli in general practice.

Akke Vellinga1, Andrew W Murphy, Belinda Hanahoe, Kathleen Bennett, Martin Cormican.   

Abstract

OBJECTIVES: A retrospective analysis of databases was performed to describe trimethoprim and ciprofloxacin prescribing and resistance in Escherichia coli within general practices in the West of Ireland from 2004 to 2008.
METHODS: Antimicrobial susceptibility testing was performed by disc diffusion methods according to the CLSI methods and criteria on significant E. coli isolates (colony count >10(5) cfu/mL) from urine samples submitted from general practice. Data were collected over a 4.5 year period and aggregated at practice level. Data on antimicrobial prescribing of practices were obtained from the national Irish prescribing database, which accounts for approximately 70% of all medicines prescribed in primary care. A multilevel model (MLwiN) was fitted with trimethoprim/ciprofloxacin resistance rates as outcome and practice prescribing as predictor. Practice and individual routinely collected variables were controlled for in the model.
RESULTS: Seventy-two general practices sent between 13 and 720 (median 155) samples that turned out to be E. coli positive. Prescribing at practice level was significantly correlated with the probability of antimicrobial-resistant E. coli with an odds ratio of 1.02 [95% confidence interval (CI) 1.01-1.04] for every additional prescription of trimethoprim per 1000 patients per month in the practice and 1.08 (1.04-1.11) for ciprofloxacin. Age was a significant risk factor in both models. Higher variation between practices was found for ciprofloxacin as well as a yearly increase in resistance. Comparing a 'mean' practice with 1 prescription per month with one with 10 prescriptions per month showed an increase in predicted probability of a resistant E. coli for the 'mean' patient from 23.9% to 27.5% for trimethoprim and from 3.0% to 5.5% for ciprofloxacin.
CONCLUSIONS: A higher level of antimicrobial prescribing in a practice is associated with a higher probability of a resistant E. coli for the patient. The variation in antimicrobial resistance levels between practices was relatively higher for ciprofloxacin than for trimethoprim.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20457673     DOI: 10.1093/jac/dkq149

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  15 in total

Review 1.  Resistance surveillance studies: a multifaceted problem--the fluoroquinolone example.

Authors:  A Dalhoff
Journal:  Infection       Date:  2012-03-30       Impact factor: 3.553

2.  Antifungal activities of different extracts of marine macroalgae against dermatophytes and Candida species.

Authors:  Elica Amara Cecilia Guedes; Maria Anilda dos Santos Araújo; Aryanna Kelly Pinheiro Souza; Larissa Isabela Oliveira de Souza; Lurdiana Dayse de Barros; Fernanda Cristina de Albuquerque Maranhão; Antônio Euzébio Goulart Sant'Ana
Journal:  Mycopathologia       Date:  2012-04-22       Impact factor: 2.574

3.  Antibiotic resistance patterns of Escherichia coli urinary isolates and comparison with antibiotic consumption data over 10 years, 2005-2014.

Authors:  P J Stapleton; D J Lundon; R McWade; N Scanlon; M M Hannan; F O'Kelly; M Lynch
Journal:  Ir J Med Sci       Date:  2017-01-04       Impact factor: 1.568

4.  Effect of Fluoroquinolone Use in Primary Care on the Development and Gradual Decay of Escherichia coli Resistance to Fluoroquinolones: A Matched Case-Control Study.

Authors:  Peter Konstantin Kurotschka; Chiara Fulgenzio; Roberto Da Cas; Giuseppe Traversa; Gianluigi Ferrante; Orietta Massidda; Ildikó Gágyor; Richard Aschbacher; Verena Moser; Elisabetta Pagani; Stefania Spila Alegiani; Marco Massari
Journal:  Antibiotics (Basel)       Date:  2022-06-18

5.  Tetracycline use in the community may promote decreased susceptibility to quinolones in Escherichia coli isolates.

Authors:  E Batard; M-A Vibet; S Thibaut; S Corvec; J Pivette; D Lepelletier; J Caillon; E Montassier
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2017-10-26       Impact factor: 3.267

6.  Foley catheters functionalised with a synergistic combination of antibiotics and silver nanoparticles resist biofilm formation.

Authors:  Rajendran Mala; Antony Annie Aglin; Arul Selvaraj Ruby Celsia; Sivalingam Geerthika; Narbahvi Kiruthika; Chinnathambi VazagaPriya; Kumarapillai Srinivasa Kumar
Journal:  IET Nanobiotechnol       Date:  2017-08       Impact factor: 1.847

7.  Opt-out as an acceptable method of obtaining consent in medical research: a short report.

Authors:  Akke Vellinga; Martin Cormican; Belinda Hanahoe; Kathleen Bennett; Andrew W Murphy
Journal:  BMC Med Res Methodol       Date:  2011-04-06       Impact factor: 4.615

8.  Antimicrobial management and appropriateness of treatment of urinary tract infection in general practice in Ireland.

Authors:  Akke Vellinga; Martin Cormican; Belinda Hanahoe; Kathleen Bennett; Andrew W Murphy
Journal:  BMC Fam Pract       Date:  2011-10-03       Impact factor: 2.497

9.  Antibiotic use in the care home setting: a retrospective cohort study analysing routine data.

Authors:  Pär-Daniel Sundvall; Beth Stuart; Martin Davis; Paul Roderick; Michael Moore
Journal:  BMC Geriatr       Date:  2015-06-25       Impact factor: 3.921

10.  Global fluoroquinolone resistance epidemiology and implictions for clinical use.

Authors:  Axel Dalhoff
Journal:  Interdiscip Perspect Infect Dis       Date:  2012-10-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.